---
reference_id: "PMID:35045221"
title: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
authors:
- Makker V
- Colombo N
- Casado Herráez A
- Santin AD
- Colomba E
- Miller DS
- Fujiwara K
- Pignata S
- Baron-Hay S
- Ray-Coquard I
- Shapira-Frommer R
- Ushijima K
- Sakata J
- Yonemori K
- Kim YM
- Guerra EM
- Sanli UA
- McCormack MM
- Smith AD
- Keefe S
- Bird S
- Dutta L
- Orlowski RJ
- Lorusso D
- Study 309–KEYNOTE-775 Investigators
journal: N Engl J Med
year: '2022'
doi: 10.1056/NEJMoa2108330
content_type: abstract_only
---

# Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
**Authors:** Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D, Study 309–KEYNOTE-775 Investigators
**Journal:** N Engl J Med (2022)
**DOI:** [10.1056/NEJMoa2108330](https://doi.org/10.1056/NEJMoa2108330)

## Content

1. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022
 Jan 19.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Makker V(1), Colombo N(1), Casado Herráez A(1), Santin AD(1), Colomba E(1), 
Miller DS(1), Fujiwara K(1), Pignata S(1), Baron-Hay S(1), Ray-Coquard I(1), 
Shapira-Frommer R(1), Ushijima K(1), Sakata J(1), Yonemori K(1), Kim YM(1), 
Guerra EM(1), Sanli UA(1), McCormack MM(1), Smith AD(1), Keefe S(1), Bird S(1), 
Dutta L(1), Orlowski RJ(1), Lorusso D(1); Study 309–KEYNOTE-775 Investigators.

Collaborators: Gomez Abuin G, Varela MS, Caceres MV, Orlando M, Capellino PH, 
Kaen DL, Cundom J, Alfie MS, Mileshkin L, Goh J, Dean A, Baron-Hay S, de Freitas 
R Jr, Bronzon Damian F, Nogueira Rodrigues A, Medeiros Milhomem Beato P, Rubini 
Liedke PE, de Melo AC, Del Pilar Estevez Diz M, Hegg R, Provencher D, MacKay H, 
Welch S, Ghatage P, Lau SKS, Sebastianelli A, Fortin S, Popowich S, Bessette P, 
Weberpals J, Oza A, Hoyos EA, Yepes A, Sanchez T, Rojas LL, Salinas J, Pierre 
ME, Restrepo JG, Madiedo O, Bustillo IJ, Selle F, Colomba E, Ray-Coquard I, 
Fabbro M, Floquet A, Chevalier-Place A, Abdeddaim C, de la Motte Rouge T, 
Joly-Lobbedez F, Lortholary A, You B, Alexandre J, Hardy-Bessard AC, Hein A, 
Wimberger P, Sehouli J, Hartkopf A, Schmalfeldt B, Duffy A, Kelly CM, Shapira R, 
Frommer F, Eitan R, Amit A, Levy T, Meirovitz M, Meirovitz A, Mangili G, Scollo 
P, Lorusso D, Raspagliesi F, Pisano C, de Giorgi U, Colombo N, Scambia G, 
Hasegawa K, Hirashima Y, Enomoto T, Itamochi H, Ushijima K, Okamoto A, Takehara 
K, Matsumoto K, Mizuno M, Sakata J, Yamagami W, Minobe S, Yonemori K, Takeshima 
N, Yunokawa M, Tokunaga H, Matsumoto T, Kobayashi H, Satoh T, Takano H, Ikeda M, 
Gómez Villanueva Á, Ceja García JP, Martínez Rodríguez JL, Castillo E, de la Luz 
García M, Wilson M, Tarnawski R, Glogowska I, Bidzinski M, Pikiel J, Okreglicka 
Lewandowska M, Jacek Symonowicz I, Danska-Bidzinska A, Cymbaluk-Ploska A, 
Igorevich Skopin P, Lisyanskaya AS, Khasanova AI, Lazarev SA, Kolomiets LA, 
Fedenko AA, Lipatov ON, Mikheeva ON, Kedrova AG, Park SY, Lim MC, Kim JW, Kim 
YM, Kim BG, Oaknin Benzaquen A, Gil Martín M, Arranz Arija JÁ, Guerra Alía EM, 
Casado Herráez A, González Martín A, Santaballa Bertrán A, Wang PH, Cheng WF, Lu 
CH, Wu CH, Chang CL, Qiu JT, Chang TC, Liou WS, Altundag O, Arik Z, Orhan B, 
Doruk H, Kanat O, Arican A, Ordu C, Mertsoylu H, Sanli UA, Krell J, Parkinson C, 
Banerjee S, McCormack M, Green C, Powell M, Herbertson R, Wilson J, Montes A, 
Kristeleit R, Holloway RW, Bell M, Celano P, Alvarez E, ElNaggar A, Garcia AA, 
Ghamande S, Graham DM, Tilley Jenkins Vogel M, Kendall SD, Konecny GE, Lewin S, 
Miller DS, Richardson DL, Moore RG, Spriggs DR, Secord A, Slomovitz B, Trent J, 
Santin A, Makker V, Aylesworth CA, Anderson C, de la Garza J, Monk B, Knowles L.

Author information:
(1)From the Department of Medicine, Memorial Sloan Kettering Cancer Center, 
Weill Cornell Medical Center, New York (V.M.); the European Institute of 
Oncology IRCCS, University of Milan-Bicocca, Milan (N.C.), Istituto Nazionale 
Tumori IRCCS-Fondazione G. Pascale, Naples (S.P.), and Fondazione Policlinico 
Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred 
Heart, Rome (D.L.) - all in Italy; San Carlos University Teaching Hospital 
(A.C.H.) and Hospital Universitario Ramón y Cajal (E.M.G.) - both in Madrid; 
Yale University School of Medicine, New Haven, CT (A.D. Santin); Gustave Roussy 
Cancerology Institute, Groupe d'Investigateurs Nationaux pour l'Étude des 
Cancers Ovariens (GINECO), Villejuif (E.C.), and Centre Léon-Bérard, University 
Claude Bernard, GINECO, Lyon (I.R.-C.) - both in France; the University of Texas 
Southwestern Medical Center, Dallas (D.S.M.); Saitama Medical University 
International Medical Center, Hidaka (K.F.), Kurume University School of 
Medicine, Kurume (K.U.), Aichi Cancer Center Hospital, Nagoya (J.S.), and 
National Cancer Center Hospital-Kokuritsu Gan Kenkyu Center Chuo Byoin, Tokyo 
(K.Y.) - all in Japan; Royal North Shore Hospital, St. Leonards, NSW, Australia 
(S.B.-H.); Sheba Medical Center, Ramat Gan, Israel (R.S.-F.); Asan Medical 
Center, University of Ulsan, Seoul, South Korea (Y.-M.K.); Ege University, 
Izmir, Turkey (U.A.S.); University College London Hospitals NHS Foundation 
Trust, London (M.M.M.), and Eisai, Hatfield (A.D. Smith) - both in the United 
Kingdom; and Merck, Kenilworth (S.K., S.B., R.J.O.), and Eisai, Woodcliff Lake 
(L.D.) - both in New Jersey.

Comment in
    Nat Rev Clin Oncol. 2022 Mar;19(3):149. doi: 10.1038/s41571-022-00604-6.
    Int J Gynecol Cancer. 2022 Apr 4;32(4):579. doi: 10.1136/ijgc-2022-003419.

BACKGROUND: Standard therapy for advanced endometrial cancer after failure of 
platinum-based chemotherapy remains unclear.
METHODS: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients 
with advanced endometrial cancer who had previously received at least one 
platinum-based chemotherapy regimen to receive either lenvatinib (20 mg, 
administered orally once daily) plus pembrolizumab (200 mg, administered 
intravenously every 3 weeks) or chemotherapy of the treating physician's choice 
(doxorubicin at 60 mg per square meter of body-surface area, administered 
intravenously every 3 weeks, or paclitaxel at 80 mg per square meter, 
administered intravenously weekly [with a cycle of 3 weeks on and 1 week off]). 
The two primary end points were progression-free survival as assessed on blinded 
independent central review according to the Response Evaluation Criteria in 
Solid Tumors, version 1.1, and overall survival. The end points were evaluated 
in patients with mismatch repair-proficient (pMMR) disease and in all patients. 
Safety was also assessed.
RESULTS: A total of 827 patients (697 with pMMR disease and 130 with mismatch 
repair-deficient disease) were randomly assigned to receive lenvatinib plus 
pembrolizumab (411 patients) or chemotherapy (416 patients). The median 
progression-free survival was longer with lenvatinib plus pembrolizumab than 
with chemotherapy (pMMR population: 6.6 vs. 3.8 months; hazard ratio for 
progression or death, 0.60; 95% confidence interval [CI], 0.50 to 0.72; P<0.001; 
overall: 7.2 vs. 3.8 months; hazard ratio, 0.56; 95% CI, 0.47 to 0.66; P<0.001). 
The median overall survival was longer with lenvatinib plus pembrolizumab than 
with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for 
death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; 
hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0.001). Adverse events of grade 3 or 
higher occurred in 88.9% of the patients who received lenvatinib plus 
pembrolizumab and in 72.7% of those who received chemotherapy.
CONCLUSIONS: Lenvatinib plus pembrolizumab led to significantly longer 
progression-free survival and overall survival than chemotherapy among patients 
with advanced endometrial cancer. (Funded by Eisai and Merck Sharp and Dohme [a 
subsidiary of Merck]; Study 309-KEYNOTE-775 ClinicalTrials.gov number, 
NCT03517449.).

Copyright © 2022 Massachusetts Medical Society.

DOI: 10.1056/NEJMoa2108330
PMCID: PMC11651366
PMID: 35045221 [Indexed for MEDLINE]